TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients
Brief Summary: Changes in chelation treatment and transfusion practices, during the past two decades, have dramatically improved the prognosis of thalassemia major patients.Deferiprone (DFP) has been compared with deferoxamine (DFO), using different schedules of treatment, in the majority of the 13 clinical trials published between 1990 and 2008.No statistically significant difference was shown between these two interventions during, at most, 18 months of treatment.Three randomised trials that compared sequential DFP-DFO treatment versus DFO alone reported controversial results but this could be due to small sample sizes and short treatment duration. In fact, no trial with treatment duration longer than 18 months15, which reported on mortality, adverse events, serum ferritin concentrations, as well as costs has so far been published.

This long-term sequential DFP-DFO treatment versus DFP alone treatment trial was conducted to assess the impacts of these chelation treatments on serum ferritin concentrations, mortality, adverse events, and costs in thalassemia major patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
B: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
C: Intervention Type: DRUG; Name: deferiprone; Assigned to Arm(s): N/A
D: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
Brief Summary: In unselected cirrhotic patients with acute portal hypertension-related bleeding to compare the effectiveness in control of bleeding, mortality rate, duration of life, quality of life, and economic costs of two widely used treatment measures: (1) emergency transjugular intrahepatic portal-systemic shunt (TIPS), and (2) emergency portacaval shunt.


Options:
A: Arm Label: Hemospray; Type: EXPERIMENTAL; Interventions: Device: Hemospray, Drug: Octreotide, Biological: Blood transfusion, Drug: Ceftriaxone | Arm Label: Non Hemospray; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide, Biological: Blood transfusion, Drug: Ceftriaxone | Intervention Type: DEVICE; Name: Hemospray; Assigned to Arm(s): Hemospray | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Hemospray, Non Hemospray | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Hemospray, Non Hemospray | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): Hemospray, Non Hemospray
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
C: Arm Label: EVL plus Somatostatin; Type: EXPERIMENTAL; Interventions: Drug: Somatostatin | Arm Label: EVL plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Somatostatin; Assigned to Arm(s): EVL plus Somatostatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EVL plus Placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
Brief Summary: In unselected cirrhotic patients with acute portal hypertension-related bleeding to compare the effectiveness in control of bleeding, mortality rate, duration of life, quality of life, and economic costs of two widely used treatment measures: (1) emergency transjugular intrahepatic portal-systemic shunt (TIPS), and (2) emergency portacaval shunt.


Options:
A: Arm Label: Ligation and Cyanoacrylate Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ligation and Cyanoacrylate | Arm Label: Ligation plus Sclerotherapy and Cyanoacrylate Group; Type: EXPERIMENTAL; Interventions: Procedure: Ligation plus Sclerotherapy and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation and Cyanoacrylate; Assigned to Arm(s): Ligation and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation plus Sclerotherapy and Cyanoacrylate Group; Assigned to Arm(s): Ligation plus Sclerotherapy and Cyanoacrylate Group
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
D: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
Brief Summary: In unselected cirrhotic patients with acute portal hypertension-related bleeding to compare the effectiveness in control of bleeding, mortality rate, duration of life, quality of life, and economic costs of two widely used treatment measures: (1) emergency transjugular intrahepatic portal-systemic shunt (TIPS), and (2) emergency portacaval shunt.


Options:
A: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
C: Arm Label: TIPS treatment; Type: EXPERIMENTAL; Interventions: Procedure: TIPS treatment | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical treatment | Intervention Type: PROCEDURE; Name: TIPS treatment; Assigned to Arm(s): TIPS treatment | Intervention Type: DRUG; Name: Medical treatment; Assigned to Arm(s): Medical treatment
D: Arm Label: Endoscopic Variceal Band Ligation (EVBL); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endoscopic Variceal Band Ligation | Arm Label: Early TIPSS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endoscopic Variceal Band Ligation, Procedure: Transjugular Intrahepatic Porto-Systemic Stent Shunt | Intervention Type: PROCEDURE; Name: Endoscopic Variceal Band Ligation; Assigned to Arm(s): Early TIPSS, Endoscopic Variceal Band Ligation (EVBL) | Intervention Type: PROCEDURE; Name: Transjugular Intrahepatic Porto-Systemic Stent Shunt; Assigned to Arm(s): Early TIPSS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
Brief Summary: In unselected cirrhotic patients with acute portal hypertension-related bleeding to compare the effectiveness in control of bleeding, mortality rate, duration of life, quality of life, and economic costs of two widely used treatment measures: (1) emergency transjugular intrahepatic portal-systemic shunt (TIPS), and (2) emergency portacaval shunt.


Options:
A: Arm Label: Carvedilol; Type: EXPERIMENTAL; Interventions: Drug: Carvedilol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Carvedilol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
C: Arm Label: Endoscopic Variceal Ligation; Type: ACTIVE_COMPARATOR; Interventions: Device: multi band ligator for esophageal varices | Arm Label: Propranolol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propranolol | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol | Intervention Type: DEVICE; Name: multi band ligator for esophageal varices; Assigned to Arm(s): Endoscopic Variceal Ligation
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm® pMDI 250/10µg (2 Puffs Bid) vs Fluticasone pMDI 250µg (2 Puffs Bid) Plus Formoterol pMDI 12µg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.
Brief Summary: The study compares the efficacy and safety of FlutiForm® vs Flixotide® plus Foradil® in the treatment of severe persisent asthma in adult subjects.


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate or formoterol/budesonide | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate or formoterol/budesonide; Assigned to Arm(s): Arm 1
C: Arm Label: Flutiform 250/10 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 250/10 micrograms | Arm Label: Flutiform 50/5 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 50/5 micrograms | Arm Label: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Arm Label: Flixotide pMDI 250 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 micrograms | Intervention Type: DRUG; Name: Flutiform 250/10 micrograms; Assigned to Arm(s): Flutiform 250/10 micrograms | Intervention Type: DRUG; Name: Flutiform 50/5 micrograms; Assigned to Arm(s): Flutiform 50/5 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Assigned to Arm(s): Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 micrograms; Assigned to Arm(s): Flixotide pMDI 250 micrograms
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin
Brief Summary: This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.


Options:
A: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin Comparator | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Metformin Comparator; Assigned to Arm(s): Metformin
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: 3.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 2.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 1.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.25 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Placebo solution, Drug: Metformin | Arm Label: Placebo/Sitagliptin (Baseline Through 104 Weeks); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo solution, Drug: Placebo tablet, Drug: Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265 | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo solution; Assigned to Arm(s): Placebo/Sitagliptin (Baseline Through 104 Weeks), Sitagliptin | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265, Placebo/Sitagliptin (Baseline Through 104 Weeks) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265, Placebo/Sitagliptin (Baseline Through 104 Weeks), Sitagliptin
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Prehospital Delay in Acute Myocardial Infarction
Brief Summary: This study was conducted to test whether a focused education and counseling intervention delivered by a nurse will decrease time of delay in seeking treatment for the signs and symptoms of acute coronary syndrome (i.e., heart attack) in patients already identified as having ischemic heart disease.


Options:
A: Arm Label: Learning and coping arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Learning and coping arm | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Learning and coping arm; Assigned to Arm(s): Learning and coping arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
B: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: educational program+telephone follow up; Type: EXPERIMENTAL; Interventions: Behavioral: educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: educational program+telephone follow up; Assigned to Arm(s): educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): usual care
C: Arm Label: Stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation | Arm Label: health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): health education
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: education | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Prehospital Delay in Acute Myocardial Infarction
Brief Summary: This study was conducted to test whether a focused education and counseling intervention delivered by a nurse will decrease time of delay in seeking treatment for the signs and symptoms of acute coronary syndrome (i.e., heart attack) in patients already identified as having ischemic heart disease.


Options:
A: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Remote Patient Monitoring | Intervention Type: DEVICE; Name: Remote Patient Monitoring; Assigned to Arm(s): Home Telemonitoring
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Care Transitions Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Transitions Intervention | Intervention Type: BEHAVIORAL; Name: Care Transitions Intervention; Assigned to Arm(s): Care Transitions Intervention
C: Arm Label: Current treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: A package of interventions; Type: OTHER; Interventions: Other: A package of interventions | Intervention Type: OTHER; Name: A package of interventions; Assigned to Arm(s): A package of interventions
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: education | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Emergency Department CT Scanning for Appendicitis: IV Contrast vs. IV and Oral Contrast
Brief Summary: The purpose of this study is to compare IV contrast only vs. IV and oral contrast Computed Tomography (CT) for the diagnosis of acute appendicitis in adult patients in our emergency department. A secondary purpose will be to design a specific CT for appendicitis protocol at our institution at the conclusion of this study.


Options:
A: Arm Label: Operative treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Appendicectomy | Arm Label: Antibiotic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ertapenem | Intervention Type: PROCEDURE; Name: Appendicectomy; Assigned to Arm(s): Operative treatment | Intervention Type: DRUG; Name: Ertapenem; Assigned to Arm(s): Antibiotic treatment
B: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Radiation: Diagnostic CT | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Diagnostic CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Low-dose CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Standard-dose CT
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Omnipaque | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Omnipaque | Intervention Type: OTHER; Name: Omnipaque; Assigned to Arm(s): 1, 2
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: appendectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: amoxicillin/clavulanate potassium | Intervention Type: DRUG; Name: amoxicillin/clavulanate potassium; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: appendectomy; Assigned to Arm(s): A

Answer: C